- Home
- COCP vs THAR Comparison
COCP vs THAR Comparison
Compare COCP & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- THAR
- Stock Information
- Founded
- COCP 2006
- THAR 2017
- Country
- COCP United States
- THAR United States
- Employees
- COCP N/A
- THAR N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- THAR Health Care
- Exchange
- COCP Nasdaq
- THAR Nasdaq
- Market Cap
- COCP 15.4M
- THAR 16.8M
- IPO Year
- COCP N/A
- THAR 2022
- Fundamental
- Price
- COCP $1.37
- THAR $2.85
- Analyst Decision
- COCP Strong Buy
- THAR Strong Buy
- Analyst Count
- COCP 1
- THAR 1
- Target Price
- COCP $6.00
- THAR $17.00
- AVG Volume (30 Days)
- COCP 4.3M
- THAR 29.4M
- Earning Date
- COCP 11-12-2025
- THAR 11-06-2025
- Dividend Yield
- COCP N/A
- THAR N/A
- EPS Growth
- COCP N/A
- THAR N/A
- EPS
- COCP N/A
- THAR N/A
- Revenue
- COCP N/A
- THAR N/A
- Revenue This Year
- COCP N/A
- THAR N/A
- Revenue Next Year
- COCP N/A
- THAR N/A
- P/E Ratio
- COCP N/A
- THAR N/A
- Revenue Growth
- COCP N/A
- THAR N/A
- 52 Week Low
- COCP $1.12
- THAR $0.95
- 52 Week High
- COCP $3.26
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- COCP 38.00
- THAR 45.88
- Support Level
- COCP $1.31
- THAR $2.75
- Resistance Level
- COCP $2.67
- THAR $3.46
- Average True Range (ATR)
- COCP 0.16
- THAR 0.81
- MACD
- COCP -0.01
- THAR -0.30
- Stochastic Oscillator
- COCP 4.42
- THAR 2.22
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.